The diagnostics developer has entered a new agreement to launch its CIZ1B biomarker test for early lung cancer detection throughout the USA, and has also agreed to a revised advance royalty payment schedule with its North American partner.
The diagnostics developer has announced the notice of its Annual General Meeting, which will be held on 30 June 2025.
The biotechnology company has announced a change in its major shareholding structure.
The diagnostics developer has raised £150,000 through a convertible loan note to support the rollout of its early cancer test in the UK and Europe, following a licensing deal in North America.
The diagnostics developer publishes its annual results, providing limited details on its progress in developing an early lung cancer detection test.
The diagnostics developer has secured its first contract in the Caribbean for its CIZ1B biomarker test, triggering early royalty payments and signaling progress in the commercialization of its technology.
The diagnostics developer has launched a new corporate website to provide information and updates to stakeholders.
The healthcare company has appointed a new non-executive director to strengthen its strategic and business capabilities.
The diagnostics developer has appointed a COLA accredited and CLIA certified lab in the US to launch its CIZ1B biomarker test for early-stage lung cancer detection.
The diagnostics developer has appointed a new Chief Scientific Officer and made progress on its lung cancer biomarker assay, positioning the company for potential growth.